• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

消胆胺引起的高氯性代谢性酸中毒。

Cholestyramine-induced hyperchloremic metabolic acidosis.

作者信息

Scheel P J, Whelton A, Rossiter K, Watson A

机构信息

Division of Nephrology, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205.

出版信息

J Clin Pharmacol. 1992 Jun;32(6):536-8. doi: 10.1177/009127009203200608.

DOI:10.1177/009127009203200608
PMID:1634640
Abstract

Cholestyramine is a nonabsorbable anion exchange resin that is used predominantly for the treatment of hypercholesterolemia in adults and the management of acute diarrhea in children. The authors report two cases of severe hyperchloremic nonanion gap metabolic acidosis associated with the use of cholestyramine therapy. The authors recommend that patients taking cholestyramine who have concomitant renal insufficiency or who are volume depleted or who are taking spironolactone be monitored carefully for the emergence of a hyperchloremic metabolic acidosis.

摘要

消胆胺是一种不可吸收的阴离子交换树脂,主要用于治疗成人高胆固醇血症和小儿急性腹泻。作者报告了两例与消胆胺治疗相关的严重高氯性非阴离子间隙代谢性酸中毒病例。作者建议,对于正在服用消胆胺且伴有肾功能不全、容量不足或正在服用螺内酯的患者,应密切监测是否出现高氯性代谢性酸中毒。

相似文献

1
Cholestyramine-induced hyperchloremic metabolic acidosis.消胆胺引起的高氯性代谢性酸中毒。
J Clin Pharmacol. 1992 Jun;32(6):536-8. doi: 10.1177/009127009203200608.
2
Cholestyramine induced hyperchloremic metabolic acidosis.
Aust N Z J Med. 1984 Oct;14(5):670-2. doi: 10.1111/j.1445-5994.1984.tb05023.x.
3
Cholestyramine induced hyperchloremic metabolic acidosis.消胆胺诱发高氯性代谢性酸中毒。
Aust N Z J Med. 1985 Apr;15(2):271. doi: 10.1111/j.1445-5994.1985.tb04032.x.
4
Hyperchloremic metabolic acidosis with cholestyramine therapy for biliary cholestasis.考来烯胺治疗胆汁淤积性黄疸所致高氯性代谢性酸中毒
Am J Dis Child. 1978 Dec;132(12):1220. doi: 10.1001/archpedi.1978.02120370072021.
5
Letter: Hyperchloremia, metabolic acidosis, and cholestyramine.信函:高氯血症、代谢性酸中毒与消胆胺。
J Pediatr. 1976 Jul;89(1):155. doi: 10.1016/s0022-3476(76)80958-4.
6
Hyperchloremic Metabolic Acidosis due to Cholestyramine: A Case Report and Literature Review.考来烯胺所致高氯性代谢性酸中毒:1例报告及文献复习
Case Rep Nephrol. 2015;2015:309791. doi: 10.1155/2015/309791. Epub 2015 Sep 3.
7
Hyperchloraemic metabolic acidosis.高氯性代谢性酸中毒
Emerg Med J. 2008 Sep;25(9):613. doi: 10.1136/emj.2008.059923.
8
Life-threatening metabolic acidosis from cholestyramine in an infant with renal insufficiency.一名肾功能不全婴儿因考来烯胺出现危及生命的代谢性酸中毒。
Am J Dis Child. 1987 May;141(5):479-80. doi: 10.1001/archpedi.1987.04460050021018.
9
Acidosis and extreme hyperkalemia associated with cholestyramine and spironolactone.
Ann Pharmacother. 1995 Feb;29(2):199-200. doi: 10.1177/106002809502900220.
10
Spironolactone-induced hyperchloremic acidosis in cirrhosis.肝硬化患者中螺内酯诱发的高氯性酸中毒
Ann Intern Med. 1979 Mar;90(3):338-40. doi: 10.7326/0003-4819-90-3-338.

引用本文的文献

1
Update of safety profile of bile acid sequestrants: A real-world pharmacovigilance study of the FDA adverse event reporting system.胆汁酸螯合剂安全性概况更新:一项关于美国食品药品监督管理局不良事件报告系统的真实世界药物警戒研究
PLoS One. 2025 Jul 15;20(7):e0328371. doi: 10.1371/journal.pone.0328371. eCollection 2025.
2
Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.前庭疾病中的药物-药物相互作用:临床问题及医学-法律影响。
Int J Environ Res Public Health. 2021 Dec 8;18(24):12936. doi: 10.3390/ijerph182412936.
3
Drug-Induced Metabolic Acidosis.
药物性代谢性酸中毒
F1000Res. 2015 Dec 16;4. doi: 10.12688/f1000research.7006.1. eCollection 2015.
4
Hyperchloremic Metabolic Acidosis due to Cholestyramine: A Case Report and Literature Review.考来烯胺所致高氯性代谢性酸中毒:1例报告及文献复习
Case Rep Nephrol. 2015;2015:309791. doi: 10.1155/2015/309791. Epub 2015 Sep 3.
5
Pharmacologically-induced metabolic acidosis: a review.药物引起的代谢性酸中毒:综述。
Drug Saf. 2010 May 1;33(5):371-91. doi: 10.2165/11533790-000000000-00000.